Skip to content

Impact of serum magnesium levels on critically ill COPD patients: A retrospective study

The effect of serum magnesium levels on criitically ill patients with chronic obstructive pulmonary disease: A retrospective observational study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12625000558426
Enrollment
265
Registered
2025-06-02
Start date
2025-02-28
Completion date
2025-04-11
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This retrospective observational study focuses on COPD patients admitted to the critical care unit. Serum magnesium levels recorded on the date of admission were retrieved from the electronic database. The primary hypothesis is that dysmagnesemia is associated with increased mortality. Additionally, the study evaluates the relationship between magnesium levels and the need for mechanical ventilation, the duration of mechanical ventilation, and the length of hospital stay.

Interventions

The relationship between serum magnesium levels and clinical outcomes, including mortality and the need for invasive or non-invasive mechanical ventilation, has yet to be thoroughly investigated specifically in COPD patients admitted to the ICU. This study aims to investigate the impact of serum magnesium levels on mortality and other clinical outcomes—such as mechanical ventilation requirements, ventilation duration, and ICU length of stay—in critically ill patients with COPD, contributing val

The relationship between serum magnesium levels and clinical outcomes, including mortality and the need for invasive or non-invasive mechanical ventilation, has yet to be thoroughly investigated specifically in COPD patients admitted to the ICU. This study aims to investigate the impact of serum magnesium levels on mortality and other clinical outcomes—such as mechanical ventilation requirements, ventilation duration, and ICU length of stay—in critically ill patients with COPD, contributing valuable insights into the management of this patient population. Relevant data, including patients’ gender, age, existing co-morbidities, serum magnesium levels on admission, mechanical ventilation status, mortality, and length of stay, will be collected from medical records, with no active participation required from the patients. The observation period will begin on the day of ICU admission and continue until the patient is discharged.

Sponsors

Ceren Önal (Agri Training and Research Hospital)
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

The study includes COPD patients over 18 years admitted to critical care unit between January 2024 and January 2025

Exclusion criteria

Patients who take magnesium supplements are excluded.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026